Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Experts explain how MRD negativity, B-cell aplasia, and CAR T persistence help predict durable remission across ALL therapies and products.

Learn how modern CAR T products differ in CRS/ICANS risk, and why earlier referral expands options for CNS and extramedullary relapse.

Experts break down how to sequence CAR T, blinatumomab, inotuzumab and transplant in relapsed ALL, balancing MRD goals, burden and toxicity.

Experts explain how MRD testing, B-cell aplasia and CAR T persistence help predict lasting ALL remission and guide transplant timing.

Expert panel shares real-world steps to start CD20xCD3 bispecifics for relapsed DLBCL, coordinating outpatient care and managing CRS/ICANS.